The scientific layer missing from your longevity investments
A continuously updated intelligence platform for family offices evaluating life sciences and longevity deals — in plain language, with real scientific rigor.
Evaluate
Every company is scored against a rigorous, literature-grounded framework covering scientific validity and commercial viability — not marketing claims.
Compare
Put up to four companies side by side across every scoring dimension and see exactly where each one sits on the Clarity Map.
Track
Add companies to a watchlist and get monitoring reports as new evidence, trials, or regulatory developments emerge.
Two scores, one clear picture
Every company is plotted on a 2x2 quadrant framework so you can instantly see the trade-off between scientific rigor and commercial readiness.
Scientific Validity Score
Mechanism novelty, mechanism validation, clinical evidence quality, translation risk, and regulatory clarity — scored 0-10 from the literature alone.
Commercial Viability Score
Market precedent, competitive landscape, time to market, IP defensibility, and funding / team traction — scored 0-10 from public commercial data.
Inside the database
Illustrative examples — the full database includes vetted companies across longevity, regenerative medicine, and biotech.
NeuroRestore Therapeutics
Senolytix Bio
Helix Diagnostics
Every score shows its work
Each assessment includes an Evidence Audit — full transparency into how many sources were searched, how many papers were found, and how much of the evidence base was actually reviewed in full text versus abstract only.
Deal Flow Intelligence
Emerging companies surfaced before they appear on PitchBook or Crunchbase — university spinouts, SBIR winners, patent clusters, and high-momentum research, pre-assessed daily by our Discovery Agent.
Example: Meridian Senolytics Lab
A representative sample of what a real Deal Flow signal looks like: a novel small-molecule senolytic identified from an NIH-funded academic lab, with early in vivo validation and a PI actively discussing licensing.
A representative example — real signals include specific evidence, scores, and a recommended next action.
Illustrative placeholder — unlock to see real, sourced risk assessments.
Example: Meridian Senolytics Lab
A representative sample of what a real Deal Flow signal looks like: a novel small-molecule senolytic identified from an NIH-funded academic lab, with early in vivo validation and a PI actively discussing licensing.
A representative example — real signals include specific evidence, scores, and a recommended next action.
Illustrative placeholder — unlock to see real, sourced risk assessments.
Example: Meridian Senolytics Lab
A representative sample of what a real Deal Flow signal looks like: a novel small-molecule senolytic identified from an NIH-funded academic lab, with early in vivo validation and a PI actively discussing licensing.
A representative example — real signals include specific evidence, scores, and a recommended next action.
Illustrative placeholder — unlock to see real, sourced risk assessments.
Available on Individual and Institutional plans
Deal Flow Intelligence surfaces emerging companies before they appear on PitchBook or Crunchbase — updated daily.
Get Early AccessWho it's built for
Family Offices
Vet deal flow before capital commitment, with scientific due diligence built in.
Private Investors
Understand what the science actually supports before you understand what the pitch says.
Investment Teams
Standardize how your team evaluates scientific risk across a growing pipeline.
Gulf Investors
Region-specific regulatory context for SFDA, DHA, and Gulf market entry considerations.
Apply for access
The Clarity Index is a vetted network of family offices and institutional investors. Apply for access and we'll review your application within 48 hours.